Showing results (181-190 of 481) with videos related to

Sort By:
Pageof 49
Human Genetics|October 2, 2010
Genetic variants in the KIF6 region and coronary event reduction from statin therapyYonghong Li, Marc S Sabatine, Carmen H Tong, et al.
American Heart Journal|December 18, 2007
Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 studyC Michael Gibson, Sabina A Murphy, Yuri B Pride, et al.
Circulation|February 6, 2004
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trialMarc S Sabatine, David A Morrow, Robert P Giugliano, et al.
Angiogenesis|September 8, 2022
MicroRNA-375 repression of Kruppel-like factor 5 improves angiogenesis in diabetic critical limb ischemiaMichael G McCoy, Anurag Jamaiyar, Grasiele Sausen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 19, 2010
Genetic regulation of platelet receptor expression and function: application in clinical practice and drug developmentMarlene S Williams, Ethan J Weiss, Marc S Sabatine, et al.
Circulation|March 21, 2007
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery diseaseMarc S Sabatine, David A Morrow, Kathleen A Jablonski, et al.
The New England Journal of Medicine|March 11, 2005
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevationMarc S Sabatine, Christopher P Cannon, C Michael Gibson, et al.
Circulation|November 18, 2005
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 TrialMarc S Sabatine, David A Morrow, Gilles Montalescot, et al.
Journal of the American College of Cardiology|July 29, 2017
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 TrialElizabeth A Magnuson, Haiyan Li, Kaijun Wang, et al.
European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Pageof 49